(Q53525194)

English

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

multicenter clinical trial

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

object named as

Bruno Sangro

6

0 references

Peter Malfertheiner

11

object named as

Peter Malfertheiner

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

10

object named as

Jerzy Walecki

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

author name string

Jens Ricke

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Karsten Bulla

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Frank Kolligs

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Markus Peck-Radosavljevic

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Peter Reimer

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Eckart Schott

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Kerstin Schütte

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Chris Verslype

9

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

SORAMIC study group

12

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

publication date

8 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

35

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

620-626

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Liver disease induced by radioembolization of liver tumors: description and possible risk factors

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Prognostic factors and prevention of radioembolization-induced liver disease

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Identifiers

10.1111/LIV.12622

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/24930619

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53525194&oldid=1963151469"